Rx Compliance Report was launched in November 2002, at the onset of the crackdown on drug marketing. It is the only source-based publication exclusively devoted to pharma sales and marketing enforcement and compliance issues. Twice a month, this 16-page newsletter examines emerging enforcement trends and offers practical advice on establishing and refining effective compliance programs. Rx Compliance Report's readers include legal, regulatory, and compliance officers from pharma, biotech and medical device companies. Dozens of drug companies of all sizes and numerous law firms have historically opted to license the newsletter on a company-wide basis.


For a limited time, Rx Compliance Report is available at the low annual rate of $795 (24 issues/year) by calling: 703/501-2019 or emailing: rxcompliance@aol.com.

To receive a rate-sheet with discount prices for multi-issue subscritons and licensing agreements, please send an email to: rxcompliance@aol.com.


  • False Claims Act investigations
  • Off-label promotion/kickback investigations
  • Foreign Corrupt Practice Act/anti-corruption
  • Drug pricing investigations
  • Managed markets/Value-based contracting
  • HIPAA/GDRP/privacy

  • Compliance program development
  • Internal audit
  • Monitoring and auditing
  • Sales force training
  • Sunshine Act/International transparency
  • Social media compliance
  • Ted Acosta, Vice Chair - Risk Management, Ernst & Young, Former Senior Attorney, HHS Office of Inspector General, New York, NY
  • Ken Berkowitz, Senior Consultant, The PharMed Group, Former Assistant General Counsel, Hoffman LaRoche, Former President, HMC Council, Tenafly, NJ
  • Regina Cavaliere, Principal, Regulatory Enforcement & Compliance, Life Sciences Sector, KPMG. Former Chief Compliance Officer & Vice President, Otsuka American Pharmaceutical, New York, NY
  • Laurence Freedman, Member, Mintz Levin, Former Assistant Director, Fraud Section, Commercial Litigation Branch, Civil Division, Department of Justice, Washington, DC
  • John Kamp, Executive Director, Healthcare Communications Council, New York, NY
  • Daniel Kracov, Co-chair, Life Sciences and Healthcare Regulatory Practice, Arnold & Porter Kaye Sholer, LLP, Washington, DC
  • Marc Raspanti, Partner, Pietragallo Gordon Alfano Bosick & Raspanti, LLP, former Assistant District Attorney, Philadelphia District Attorney's Office, Philadelphia PA
  • William Sarraille, Partner, Sidley, Washington DC
  • Paul Silver, Principal, Regulatory & Compliance Life Sciences Leader, Deloitte Advisory, Atlanta, GA
  • Michael Shaw, Vice President & Compliance Officer, GlaxoSmithKline-NA Pharmaceuticals, Former Senior Counsel, HHS Office of Inspector General, Philadelphia, PA

Order Now | Free Trial | About the Publisher | Testimonials | Copyright Policy | Contact Us

All material on this website is protected by copyright.
© Rx Compliance Report.
All rights reserved.